Strides Shasun a buying opportunity, ROE to clock 20%: Centrum

Kunj Bansal of Centrum Wealth Management told CNBC-TV18, "Strides Shasun is one stock from the pharma space which had the least or no effect of demonetisation and will not have going forward as well. Although the compant declared a modest topline growth of 8 percent Y-o-Y, but its margins improved sharply, there was a 30 percent growth in EBITA to almost Rs 200 crore. With that, its margins have moved up to Rs 15-16 percent compared to 12 percent.""With the returm on equity (ROE) likely to move to 20 percent, I think that is one of the companies that offers a very good buying opportunity," he said.